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Endoluminal Femoropopliteal Bypass for Intermittent Claudication
P. V. Tisi*, A. R. Cowan and G. E. Morris
Department of Vascular Surgery, Southampton General Hospital, Southampton, U.K.
Objectives: (i) to describe our initial clinical experience with endoluminal femoropopliteal bypass using a technique
developed in a cadaveric model; (ii) to identify areas requiring technical modification to improve patency and complication
rates.
Design: prospective, experimental pilot study.
Materials and methods: fourteen consecutive patients with disabling intermittent claudication and superficial femoral
artery occlusion underwent endarterectomy through a groin incision and endoluminal placement of a polytetrafluoroethylene
graft. Follow-up was by duplex ultrasound and arteriography.
Results: two endovascular technical failures required conversion to open surgery. The cumulative primary (1o), 1o-
assisted and secondary (2o) patency rates at 1 year were 35.7%, 42.8% and 71.4% respectively; at 2 years the patency
rates were 14.3%, 31.2% and 57.1%. Twenty-three endovascular interventions were required to maintain graft patency
in 10 patients. Five patients subsequently required conventional bypass, of whom two proceeded to major amputation
because of graft infection. Seven endovascular grafts remain patent at a mean follow-up of 50 months.
Conclusions: this minimally invasive surgical technique is feasible, with acceptable patency rates. However, considerable
investment of time and resources is required to maintain graft patency. With increasing experience and improved technical
design, this procedure may offer a real alternative to conventional surgery in patients disabled by short-distance
claudication.
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Introduction reported series according to these criteria and showed
a 5-year patency of only 38.1% for femoral–popliteal
The majority of patients with stable intermittent clau- angioplasty.6 Conventional bypass with all its at-
tendant risks is difficult to justify for the majoritydication can be treated by conservative measures such
as stopping smoking, regular exercise and losing of patients and is generally reserved for those with
incapacitating short-distance claudication or patientsweight. This is often supplemented by aggressive lipid-
lowering therapy,1 antiplatelet treatment2 and thera- with critical limb ischaemia.
With the current trend towards minimally invasivepeutic exercise training,3 although the latter is in-
frequently used outside of a research setting. There surgery, there has been renewed interest in alternative
surgical options for patients with intermittent clau-remains some controversy as to the best treatment for
the 20–25% of claudicants who deteriorate despite dication. Parodi et al. demonstrated the feasibility of
endovascular insertion of a stent graft for abdominalthese simple measures.4 For localised superficial fem-
oral artery occlusive disease, percutaneous trans- aortic aneurysm in 1991.7 This has now become an
established technique, although numerous clinicalluminal angioplasty (PTA) is generally considered as
the next line of treatment. However, long-term patency trials remain in progress, particularly with respect
to the durability of the procedure. The concept ofrates for femoral–popliteal angioplasty are dis-
appointing if the criteria of the American Society for endoluminal bypass can also be applied to superficial
femoral artery (SFA) occlusive disease. We have pre-Vascular Surgery/International Society for Cardio-
vascular Surgery (SVS/ISCVS) are strictly adhered viously demonstrated the feasibility of endoluminal
bypass for superficial femoral artery occlusive diseaseto.5 For example, Johnston re-analysed his previously
in a cadaveric study.8 This paper reports our initial
clinical experience with the technique and describes
* Please address all correspondence to: P. V. Tisi, Department of how the technique has been modified during the learn-Vascular Surgery, Royal Bournemouth Hospital, Castle Lane East,
Bournemouth, Dorset BH7 7DW, U.K. ing curve.
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Materials and Methods
This pilot study reports a consecutive series of 14 cases
of endoluminal femoropopliteal bypass performed be-
tween December 1994 and April 1997. Ethical approval
for the study was obtained from Southampton and
South West Hampshire Health Commission.
Potential subjects aged over 35 years referred with
lifestyle-threatening intermittent claudication were re-
cruited from the Vascular Surgical Clinic. Following
standard outpatient assessment by history, clinical
examination and non-invasive duplex ultrasound,
patients with severe intermittent claudication under-
went diagnostic digital subtraction angiography, ac-
cording to departmental protocol. Patients with critical
limb ischaemia were excluded from the study. Angio-
graphic criteria for inclusion into the study were
deemed to be an absence of significant disease prox-
imal to the common femoral artery, extensive super-
ficial femoral artery disease not amenable to
percutaneous transluminal angioplasty (multiple high-
grade stenoses, an occlusion of [8 cm, a combination
of stenotic and occlusive disease or restenosis fol-
lowing previous PTA), a patent above-knee popliteal
segment and at least two patent crural vessels in
continuity. Suitable patients were fully counselled
about the study and informed consent obtained if they
Fig. 1. On-table digital subtraction arteriogram showing occlusionwere in agreement.
of the superficial femoral artery.The surgical technique for endovascular bypass has
been described previously.8 The modified procedure
is described below. The procedure is performed using A thin-walled polytetrafluoroethylene (PTFE) graft
digital subtraction angiography in the operating room. (5–6 mm diameter) (WL Gore & Associates) is then
The common femoral bifurcation is exposed via a placed transluminally using a specially designed in-
small groin incision with control of inflow and outflow strument (ForcepsTM, EndoVascular Instruments Inc.)
vessels. A downstream arteriogram is then performed and deployed using a balloon to conform to the dia-
by direct puncture (Fig. 1). A 5F sheath is inserted meter of the native SFA. The graft, interface and pop-
into the SFA through a small common femoral ar- liteal artery are then examined with an angioscope. A
teriotomy. A 0.035 uncoated guidewire is then used conventional end-to-end proximal anastomosis is then
to cross the diseased segment into the healthy below- performed between the graft and the femoral artery.
knee popliteal artery. The distal interface is determined A completion arteriogram then confirms patency of
angiographically and marked on the skin surface. In the graft (Fig. 3).
cases of failed passage of a guidewire, a Dynamic Patient follow-up was by clinical assessment and
Introducer DilatorTM (EndoVascular Instruments Inc., surveillance using duplex ultrasound and Doppler
Portland, OR, U.S.A.) was used to obtain endovascular ankle–brachial pressure index every 6 weeks up to 6
access followed by exchange with an uncoated wire. months. Arteriography was performed in the event
The SFA is then mechanically dilated with the rotating of recurrence of claudication symptoms or duplex
Dynamic DilatorTM (EndoVascular Instruments Inc.), evidence of a problem with the endovascular graft.
using interchangeable heads ranging from 3 to 5 mm Graft patency was maintained using radiological inter-
in diameter. An expandable helical cutter (Expandable vention (such as recombinant tissue plasminogen ac-
CatheterTM, EndoVascular Instruments Inc.) is then tivator (rTPA) thrombolysis by low-dose infection or
used to endarterectomise the SFA in 5-cm incremental pulse-spray techniques, percutaneous transluminal
passes until the distal interface is reached (Fig. 2). This angioplasty +/- stenting and mechanical throm-
bolysis (Cordis Hydrolyser)) or surgery (for example,distal endpoint is then dilated with a 6-mm balloon.
Eur J Vasc Endovasc Surg Vol 19, May 2000
Endoluminal Femoropopliteal Bypass 483
Fig. 3. Completion arteriogram following placement of an endo-Fig. 2. Arteriographic appearance following superficial femoral
luminal graft.endarterectomy. The ‘Bulldog’ clip marks the distal point of the
endarterectomy in the above-knee popliteal segment.
(common iliac artery in one patient and superficialgraft thrombectomy and patch angioplasty). Failed
femoral artery in two patients). Digital subtractiongrafts were salvaged by conventional bypass surgery
angiography showed diffuse SFA disease in twoif symptomatic. There was no routine policy for post-
patients, a long SFA occlusion in seven patients (meanoperative anticoagulation, although the majority of
length 19.6 cm and both stenotic and occlusive SFApatients (n=8) were commenced on warfarin either
lesions in five patients (mean occlusion length 5.8 cm).immediately postoperatively or following intervention
Technical problems with the procedure were en-to maintain graft patency.
countered in 10 patients (71.4%), mostly due to dif-Patency rates were reported according to the SVS/
ficulties crossing the lesion with a guidewire (n=6),ISCVS criteria as previously mentioned5 and analysed
equipment failure (n=3) and thromboembolism (n=using the life-table method.9
3). In seven cases, problems were overcome using
endovascular techniques. In one patient, the procedure
failed due to graft thrombosis and a dissection flap at
the distal graft–vessel interface, while a second caseResults
failed due to vessel perforation, resulting in a technical
failure rate of 14.3%. Both cases were salvaged byEleven men and three women were recruited with a
median age of 67 years. Thirteen subjects had calf immediate reconstructive surgery, with one graft
(femoro-above-knee-popliteal PTFE graft) remainingclaudication only, while one complained of buttock,
thigh and calf claudication. The mean reported max- primarily patent at >28 months. The second graft
(femoro-below-knee-popliteal vein bypass) requiredimum walking distance was 99 m (range 46–229 m).
Eleven patients had no previous history of intervention three interventions before occluding at 31 months.
Cumulative patency rates according to ‘intention tofor peripheral arterial disease: three had undergone a
previous balloon angioplasty to the ipsilateral limb treat’ (i.e. including primary graft failures) are shown
Eur J Vasc Endovasc Surg Vol 19, May 2000
P. V. Tisi et al.484
Fig. 4. Cumulative primary and secondary patency rates for endo-
luminal grafts. Number of grafts “at risk” for each time interval are
shown.
graphically in Figure 4. Primary (1o), 1o-assisted and
secondary (2o) graft patency at 12 months was 35.7%,
42.8% and 71.4% respectively: at 24 months, patency
was 14.3%, 31.2% and 57.1%. The standard error of
the mean cumulative patency was >10% at all time
intervals for primary and primary-assisted patency
and >10% from 3 months for secondary patency. Three
grafts occluded within the first 24 h, due to hypo-
tension and damage from vascular clamps. All three
were successfully salvaged using rTPA thrombolysis
(n=2) or graft thrombectomy n=1).
Seven endovascular grafts remain patent at a mean
follow-up of 50 months (Fig. 5 and Fig. 6). This required
a total of 23 interventions to maintain graft patency,
of which five were in the perioperative phase and 18
in the follow-up phase. The majority of these inter-
ventions (n=18) were required in five patients, while
a further five patients required one intervention only.
Interventions included rTPA thrombolysis (seven
patients), angioplasty +/- stenting (nine patients),
Fig. 5. Arteriogram showing the common femoral bifurcation andmechanical thrombolysis (two patients) and surgical endoluminal graft at 4 years’ follow-up.
graft thrombectomy (two patients) (Table 1).
Five patients underwent reconstructive surgery fol- formation, thrombosis of a revision iliopopliteal ob-
lowing occlusion of a previously patent endovascular turator bypass (using long saphenous vein) and sub-
graft, i.e. femoropopliteal vein or Dacron bypass. In sequent high above-knee amputation. This last case
three patients, these grafts remained patent, while two was complicated by pulmonary oedema and acute
patients underwent major amputation, in both cases renal failure secondary to sepsis and diabetic neph-
due to methicillin-resistant Staphylococcus aureus ropathy, which required temporary haemodialysis.
(MRSA) infection. In the first case, MRSA infection The mortality to date is zero.
of a femoropopliteal vein graft occurred (following
endovascular graft occlusion) leading to secondary
haemorrhage from the graft. This was revised to a
femorodistal graft using vein from the arm, but con- Discussion
tinuing sepsis resulted in a below-knee and sub-
sequently an above-knee amputation. In the second Conventional surgery currently has a very limited
role in the management of intermittent claudication.case, MRSA infection of the groin wound occurred,
leading to endovascular graft infection, false aneurysm Above-knee femoropopliteal bypass carries a 4-year
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SFA disease not suitable for transluminal dilatation.
Subintimal angioplasty may overcome this problem
by creating a smooth neo-lumen, although the long-
term results are unknown. Primary and secondary
patency rates of 59% and 79% at 2 years have been
reported for a series of infrapopliteal subintimal di-
latations.13 Subintimal angioplasty is very operator-
dependent, with the most frequently reported problem
being failure to re-enter the true vessel lumen distal
to the disease. Interestingly, two cases of spontaneous
formation of a communication between the neo-lumen
and the true lumen following failed subintimal an-
gioplasty have been recently reported.14
There has been renewed interest in semi-closed end-
arterectomy for SFA occlusive disease. Van der Heijden
reported a series of 259 cases using this technique, in
which a ring stripper was introduced via arteriotomies
in both common femoral and above-knee popliteal
arteries.15 The technical success rate was 89% with a
5-year secondary patency of 61%, which compares well
with conventional bypass surgery. Moll and colleagues
reported a less invasive refinement of this technique,
using a ring stripper to define the endarterectomy
plane through a single groin incision, followed by a
Mollring Cutter (Avatar Inc., Portola Valley, CA,
U.S.A.) to divide the intimal core distally, and sub-
sequent deployment of a stent at the distal interface.
The initial results from 38 cases reported 100% tech-
nical success rate with 1o and 2o patency rates of 80%
and 85% at 1 year.16 Intermediate follow-up suggests
a 2o patency of 86% at 2 years.17 Whiteley et al. suc-
cessfully completed this technique in 80.8% of 26
limbs, with a 1o patency of 85.7% at 30 days.18 The
intermediate results are as good as conventional by-
pass, but the long-term results of this technique are
less encouraging.19 The problem with such extensive
endarterectomy is that the risks of restenosis are con-Fig. 6. Arteriogram showing the distal graft–vessel interface and
siderable. This is the concept behind ‘‘relining’’ thepopliteal trifurcation at 4 years’ follow-up.
SFA with a transluminally placed graft.
The concept of endoluminal grafting was first re-patency of 60–70%, while the patency of below-knee
ported by Volodos et al.20 Endoluminal grafting is nowfemoropopliteal bypass ranges from 40% for ePTFE to
widely accepted as a method of abdominal aortic70% for long saphenous vein.10 However, surgery has
aneurysm exclusion, although the durability of thea significant early complication rate, although this can
procedure is as yet unproven. For this method tobe reduced by the use of regional anaesthesia11 and
be applicable to superficial femoral artery occlusivecareful preoperative assessment.12 Graft occlusion may,
disease, recanalisation of the lumen is necessary beforehowever, precipitate the patient into critical limb isch-
insertion of a stent graft. Cragg and Dake dem-aemia, which has a significantly worse prognosis in
onstrated the feasibility of balloon dilatation followedterms of limb salvage and mortality. There is a sig-
by endoluminal stent-graft insertion in a small seriesnificant group of claudicants (20–25%) who continue
of patients.21 However, this is fraught with the sameto be incapacitated by symptoms despite simple meas-
problems as conventional angioplasty, i.e. balloon di-ures such as risk-factor modification, exercise and
latation of calcified diseased vessels leads to significantantiplatelet treatment. Conventional PTA has a limited
role in these patients, as there is frequently diffuse vessel elastic recoil. This could lead to endoluminal
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Table 1. Intervention required to maintain endovascular graft patency in 14 cases (rTPA=tissue plasminogen activator, PTA=
percutaneous transluminal angioplasty).
Case Intervention rTPA PTA PTA proximal PTA distal PTA Mechanical Graft
no. episodes thrombolysis inflow interface interface outflow thrombolysis thrombectomy
– patch
1 3 2 2 1
2 1 1 1 1
3 1 1
4 1 1 Stent 1
5 0
6 0
7 5 5 1+1 Stent 2 1
8 Failure
9 1 1
10 5 4 3 2+1 Stent 1
11 Failure
12 3 3 1 Stent 2+1 Stent 1
13 1 Stent
14 2 1 Stent 1 1
graft failure secondary to ‘‘extrinsic’’ stenoses (i.e. these series involves endovascular access to the com-
mon femoral artery (either percutaneous or by formalreduction in endoluminal graft diameter) resulting
from this recoil.22 The problem may be offset by de- surgical exposure, arteriotomy and insertion of a
sheath), placement of a guidewire through the diseasebulking the vessel (i.e. endarterectomy or atherectomy)
followed by endoluminal graft placement. Stenting and balloon dilatation of the SFA, transluminal place-
ment of an ePTFE graft and deployment of a stent (e.g.of the distal interface will also reduce elastic recoil,
although it is important that the stent itself should not Palmaz) at the distal graft–vessel interface. Spoelstra
reported 1o and 2o patency rates of 73.1% and 86.3%be in contact with the arterial wall, as exposure appears
to encourage neointimal hyperplasia.23 at 1 year (55 patients),20 while Diethrich reported 1o
and 2o patency rates of 72% and 84% at 8 months’The feasibility of our technique of endoluminal by-
pass was assessed in a cadaveric study. The procedure follow-up (50 patients).30 Henry et al. reported a series
of 204 stent grafts using the Cragg Endopro System 1was successfully completed in 81% of 48 limbs.24 On-
table angiography and histological examination of the (now developed as the Passager (Boston Scientific,
Meadox Medicals, Oakland, NJ, U.S.A.)), a self-explanted vessels showed a smooth distal graft–vessel
interface in 62% of limbs. The abnormalities found on expanding nitinol stent covered by a heparin-bonded
Dacron graft.31 For femoropopliteal lesions, 1o and 2ohistology and angiography included contrast extra-
vasation, a distal intimal flap and a distal fold in the patency rates of 64% and 76% were found at 27 months.
Van Urk in a pilot study of the ENDURING (WL Goregraft. Ahn and colleagues also reported the same
cadaveric technique with similar results.25 There has & Associates) reported a series of transluminal ePTFE
grafts without stenting, with a technical success ratebeen little in the way of clinical trials of initial endo-
vascular debulking of the atheroma followed by trans- of 75%.32 Follow-up was only reported to 2.5 months,
however. Bleyn reported early results from a newluminal graft placement. Moll and Ho have taken the
use of the Mollring Cutter (as described above) a stage stent-graft (Hemobahn (WL Gore & Associates)) con-
sisting of an ePTFE inner lining with an external nitinolfurther by relining the vessel with an ePTFE graft, in
order to overcome the 46% restenosis rate in their self-expanding stent.33 Sixty-one limbs were treated
with 1o and 2o patency rates of 83% and 86% at 6original series.26 The reported secondary patency rate
at 2 years in a series of 14 cases was 70%. Bergeron et al. months. Further results from this technique are again
awaited with interest.have also used a Vollmar ring stripper and a Mollring
Cutter to endarterectomise the SFA, followed by trans- Newer surgical techniques such as endoluminal by-
pass have specific problems and complications as-luminal placement of a balloon-expandable ePTFE
graft and deployment of a Palmaz stent at the distal sociated with them. Interestingly, Hayoz showed that
patients treated with an endoluminal stent graft (Cragginterface.27
Other authors have reported their experience with EndoPro System 1) mounted a greater inflammatory
response (pyrexia, erythema and tenderness over theendoluminal femoropopliteal bypass using ‘‘non-
debulking’’ techniques.28,29 The basic technique in all graft site and elevated serum acute-phase proteins)
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than patients simply treated with a nitinol stent.34 There is undoubtedly a significant learning curve
associated with this procedure. We expect that sig-One of the major challenges in vascular surgery is
to overcome the problem of neo-intimal hyperplasia nificantly improved patency rates may be achieved
with the current rapid development in graft technologywhich decreases the life expectancy of vascular grafts
in general, although is a specific problem for (i.e. balloon-expandable fully supported ePTFE grafts)
and delivery systems. Endovascular femoropoplitealendoluminal grafts. Ohki35 recently reported an ex-
perimental study in dogs, which showed increased bypass could therefore become the treatment of choice
in this selected group of patients.distal ‘‘anastomotic’’ stenosis, intimal thickening and
endothelialisation at 8 weeks in animals treated with
an iliac stent graft compared to those treated with a
conventional ePTFE graft. Marin et al. examined 7
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